DURHAM, N.C.--(BUSINESS WIRE)--Biomarck Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company developing anti-inflammatory and oncological therapies that target the MARCKS protein, today announced the appointment of Dr. Graham G. Lumsden as President and Chief Executive Officer.
“We are pleased to welcome Graham to Biomarck. He brings a wealth of experience in pharmaceuticals and biotechnology to this company as we initiate the next phase of clinical trials in 2021,” said Rajin Ahuja, Executive Chairman of Biomarck. “Graham is the right leader at the right time to advance our clinical programs in Acute Respiratory Distress Syndrome (ARDS), Chronic Obstructive Pulmonary Disease (COPD) and Non-Small Cell Lung Cancer (NSCLC), together with the other assets in our portfolio, in 2021 and beyond.”
Before joining Biomarck, Dr. Lumsden served as CEO of Motif Bio where he raised $125 million, including two IPOs (AIM and NASDAQ), to advance iclaprim, a targeted antibacterial, through Phase 3 and NDA submission. Prior to Motif, he founded and was the CEO of Tiemed LLC, a biotech company developing solutions for patients with difficulties taking oral medicines. Dr. Lumsden also spent over 20 years at Merck & Co., Inc., where he gained global expertise in both veterinary and human health, including worldwide businesses at Merck with annual revenues of more than $1 billion. Dr. Lumsden brings extensive domestic and international senior leadership experience in pharmaceuticals and biotechnology, including capital markets, corporate governance, new product launches, including Fosamax ® Plus D, preclinical and clinical development, regulatory strategy, sales and marketing, business development, CMC and IP strategy.
Dr. Lumsden received his Bachelor of Veterinary Medicine & Surgery from University of Edinburgh, U.K. and his Postgraduate Diploma in Marketing from the Chartered Institute of Marketing in the U.K.
“Given the demonstrated benefits for patients of medicines targeting the MARCKS protein, this is a great opportunity to build on the work of the Biomarck team to date,” said Dr. Lumsden. “In addition to the respiratory lead programs, this mechanism lends itself to other indications where patients currently have limited or no therapeutic options. I am excited to join the team and look forward to executing on Biomarck’s mission of delivering proven therapies for patients with inflammatory, oncological and other difficult to treat diseases.”
About Biomarck Pharmaceuticals, Ltd.
Biomarck is a biopharmaceutical company focused on the development of drugs to treat ARDS, COPD, cancer and other hard to treat diseases. With over 100 patented peptides in our global portfolio, we utilize anti-MARCKS proteins to selectively inhibit cancer progression and the inflammatory cytokine release involved in respiratory diseases and other severe illnesses. Learn more about our platform technology and how we are developing safe and targeted treatments for patients in need at www.biomarck.com.
